Prime Medicine: Chardan Capital maintains Buy rating, lowers PT to $9.

Monday, Nov 10, 2025 7:32 am ET1min read
PRME--

Prime Medicine: Chardan Capital maintains Buy rating, lowers PT to $9.

Prime Medicine: Chardan Capital maintains Buy rating, lowers PT to $9.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet